Guchong Pharmaceutical

Guchong Pharmaceutical is a Shanghai-based biotechnology company dedicated to the discovery and development of innovative small molecule therapeutics targeting the Hippo signaling pathway. The company focuses on "undruggable" targets that play pivotal roles in tumor growth, metastasis, and drug resistance. Its primary research efforts are directed toward the YAP/TAZ-TEAD transcription complex, a key regulator of cell proliferation and survival. Guchong's lead candidate, GC001, is a potent and selective TEAD inhibitor designed for the treatment of solid tumors, including mesothelioma and cancers with NF2 mutations. By leveraging its deep expertise in structural biology and medicinal chemistry, the company aims to deliver breakthrough precision medicines for oncology and beyond. The firm is backed by prominent venture capital investors including HighLight Capital and Sherpa Healthcare Partners.